GlaukosGKOS
About: Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Employees: 995
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
68% more repeat investments, than reductions
Existing positions increased: 138 | Existing positions reduced: 82
11% more capital invested
Capital invested by funds: $5.65B [Q1] → $6.29B (+$639M) [Q2]
5.9% more ownership
Funds ownership: 100.64% [Q1] → 106.54% (+5.9%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]
8% less funds holding
Funds holding: 315 [Q1] → 291 (-24) [Q2]
30% less first-time investments, than exits
New positions opened: 46 | Existing positions closed: 66
50% less call options, than puts
Call options by funds: $21.4M | Put options by funds: $43M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Wells Fargo Larry Biegelsen | 0%upside $92 | Equal-Weight Maintained | 31 Jul 2025 |
UBS Danielle Antalffy | 46%upside $134 | Buy Maintained | 31 Jul 2025 |
Financial journalist opinion
Based on 6 articles about GKOS published over the past 30 days
